This step would contribute to a more comprehensive understanding of the regenerative properties of chimeric FGF21/HGFR and its potential as a therapeutic intervention for non-alcoholic fatty liver disease in humans. The gene discussed is MET; the disease is metabolic dysfunction-associated steatotic liver disease.